Trials / Completed
CompletedNCT02970292
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 396 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin | Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth |
| DRUG | Placebo | Placebo, taken as two tablets, once daily by mouth |
Timeline
- Start date
- 2016-10-26
- Primary completion
- 2019-05-28
- Completion
- 2019-06-25
- First posted
- 2016-11-22
- Last updated
- 2020-06-17
- Results posted
- 2020-06-17
Locations
105 sites across 10 countries: United States, Bulgaria, Canada, Czechia, Hungary, Lithuania, Poland, Russia, Serbia, Ukraine
Source: ClinicalTrials.gov record NCT02970292. Inclusion in this directory is not an endorsement.